echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: CD4, CD8 and FOXP3 positive immune cells can be used as predictors of BRCA1/2-related breast cancer mortality

    Br J Cancer: CD4, CD8 and FOXP3 positive immune cells can be used as predictors of BRCA1/2-related breast cancer mortality

    • Last Update: 2021-08-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    About 3-5% of breast cancer patients have BRCA1 or BRCA2 gene mutations, which is the cause of about 28% of high-risk hereditary breast cancers
    .


    Previous studies have shown that BRCA1/2 mutation carriers have an increased risk of developing contralateral breast cancer, the risk of BRCA1 mutations is the highest, and the patientsare younger when they arefirst diagnosed with breast cancer


    About 3-5% of breast cancer patients have BRCA1 or BRCA2 gene mutations, which is the cause of about 28% of high-risk hereditary breast cancers


    The two breast cancer susceptibility genes BRCA1 and BRCA2 are located on chromosomes 17 and 13, respectively.
    Mutations in the BRCA gene can lead to DNA repair defects and an increased risk of early-onset breast cancer
    .

    The prognostic value of tumor infiltrating lymphocytes (TIL) in breast cancer has been recognized
    .


    However, there are still few studies on specific T cell subsets of BRCA-related breast cancer


    Distribution of immune marker expression

    Immunological marker expression profile of immune

    In this study, the researchers analyzed tumor tissues from 414 breast cancer patients with BRCA mutations, and detected the expression levels of CD4, CD8, and FOXP3 immune markers through immunohistochemistry and digital image analysis
    .


    According to the analysis of low expression group or high expression group, the distribution and clinicopathological characteristics of CD4, CD8 and FOXP3 positive cells were evaluated


    The researchers analyzed tumor tissues from 414 breast cancer patients with BRCA mutations, and used immunohistochemistry and digital image analysis to detect the expression levels of CD4, CD8 and FOXP3 immune markers


    Analysis of patient survival rate

    Analysis of patient survival rate

    The results showed that the expression levels of CD4 and CD8 were related to the histological diagnosis of the disease, tumor grade, and the expression status of estrogen and progesterone receptors
    .


    The expression level of CD4 is correlated with BRCA gene status



    All in all, the results of this study support the prognostic role of specific T cell subsets in BRCA-associated breast cancer and the potential of targeting the immune system to treat the disease
    .


    The results of this study support the prognostic role of specific T cell subsets in BRCA-related breast cancer and the potential of targeting the immune system to treat the disease
    .


    The results of this study support the prognostic role of specific T cell subsets in BRCA-related breast cancer and the potential of targeting the immune system to treat the disease



    Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.